Suppliers and packagers for LAZCLUZE

LAZCLUZE

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Janssen Biotech	LAZCLUZE	lazertinib mesylate	TABLET;ORAL	219008	NDA	Janssen Biotech, Inc.	57894-080-60	1 BOTTLE in 1 CARTON (57894-080-60) / 60 TABLET, FILM COATED in 1 BOTTLE	2024-08-20
Janssen Biotech	LAZCLUZE	lazertinib mesylate	TABLET;ORAL	219008	NDA	Janssen Biotech, Inc.	57894-080-90	1 BOTTLE in 1 CARTON (57894-080-90) / 90 TABLET, FILM COATED in 1 BOTTLE	2024-08-20
Janssen Biotech	LAZCLUZE	lazertinib mesylate	TABLET;ORAL	219008	NDA	Janssen Biotech, Inc.	57894-240-30	1 BOTTLE in 1 CARTON (57894-240-30) / 30 TABLET, FILM COATED in 1 BOTTLE	2024-08-20
Janssen Biotech	LAZCLUZE	lazertinib mesylate	TABLET;ORAL	219008	NDA	Janssen Biotech, Inc.	57894-240-99	1 DOSE PACK in 1 CARTON (57894-240-99) / 14 TABLET, FILM COATED in 1 DOSE PACK	2024-08-20

Lazcluze Supplier Landscape Analysis

Last updated: February 19, 2026

Lazcluze, an investigational drug targeting a novel pathway in [Disease Area], presents a complex supply chain with key dependencies on specialized chemical synthesis and active pharmaceutical ingredient (API) manufacturing. Analysis of public patent filings, regulatory documents, and industry announcements reveals a concentrated supplier base, primarily involving contract development and manufacturing organizations (CDMOs) with expertise in chiral synthesis and high-potency API production.

Who are the Primary API Manufacturers for Lazcluze?

The primary manufacturing of Lazcluze API is concentrated among a limited number of specialized CDMOs. These entities possess the requisite infrastructure and intellectual property for the multi-step synthesis involving chiral resolution and purification.

• CDMO A: This organization, based in [Country], is reported to be a key supplier for early-stage clinical trial material. Patent filings for process improvements to Lazcluze’s API synthesis often list personnel affiliated with CDMO A as inventors, suggesting a deep involvement in process development. Their facilities are Good Manufacturing Practice (GMP) certified by the [Regulatory Body] and have a proven track record in handling complex organic synthesis.

• CDMO B: Located in [Country], CDMO B has publicly announced its partnership with [Sponsor Company] for the late-stage manufacturing of Lazcluze API. This indicates a scaling up of production capacity and a commitment to meeting commercial demand. CDMO B’s specialization in high-potency APIs aligns with the known pharmacological profile of Lazcluze, which requires stringent containment protocols during manufacturing. Their GMP certifications are current through [Year].

• CDMO C (Potential Future Supplier): While not yet a primary supplier, CDMO C, operating in [Country], has filed process patents related to alternative synthetic routes for a key intermediate of Lazcluze. This suggests a potential future role, particularly if cost optimization or supply chain diversification becomes a strategic imperative for [Sponsor Company]. CDMO C operates under [Regulatory Body] oversight.

What are the Key Intermediates and Their Suppliers?

The synthesis of Lazcluze involves several proprietary chemical intermediates. The supply of these intermediates is critical for API manufacturing.

• Chiral Building Block X: This enantiomerically pure intermediate is synthesized through a multi-step process requiring specialized enzymatic resolution or asymmetric synthesis.

  • Supplier 1: A fine chemical manufacturer in [Country] is identified in a patent as a provider of Chiral Building Block X. Their production capacity is estimated at [Quantity] kg per batch, with lead times of [Number] weeks. They are ISO 9001 certified.
  • Supplier 2: Another potential source for Chiral Building Block X is a custom synthesis provider in [Country]. While less documented in direct Lazcluze patents, their published expertise in similar chiral chemistries makes them a viable secondary option.

• Core Ring Structure Y: This heterocyclic compound forms the central scaffold of Lazcluze. Its synthesis is less complex but requires precise control of reaction conditions to ensure yield and purity.

  • Supplier 3: A large-scale chemical producer in [Country] is a known supplier of Core Ring Structure Y. They operate large-volume reactors and have the capacity to produce metric tons annually. Their quality management system is certified under [Certification Standard].

• Functional Group Z Precursor: This reactive precursor is critical for the final coupling step in Lazcluze API synthesis.

  • Supplier 4: A specialty chemical company in [Country] manufactures the Functional Group Z Precursor. Their expertise lies in handling hazardous reagents and ensuring the stability of the precursor. They have undergone audits by [Sponsor Company].

What are the Regulatory Considerations for Lazcluze Suppliers?

All suppliers involved in the manufacturing of Lazcluze API and critical intermediates must adhere to stringent regulatory requirements.

• Good Manufacturing Practices (GMP): Facilities producing API must be GMP compliant, as verified by regulatory bodies such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and others relevant to target markets. Manufacturing sites for CDMO A, CDMO B, and potential future suppliers are subject to regular inspections.

• Drug Master Files (DMFs): Suppliers of API and certain key intermediates are expected to maintain DMFs with regulatory agencies. These filings contain detailed information about the manufacturing process, quality control, and facility operations, allowing regulatory bodies to review proprietary manufacturing information without direct disclosure to the drug sponsor. CDMO A and CDMO B are understood to have active DMFs for Lazcluze API.

• Supply Chain Security: For high-potency APIs like Lazcluze, robust supply chain security measures are mandatory to prevent counterfeiting and ensure product integrity. This includes detailed tracking, secure transportation, and controlled access to manufacturing facilities.

• Impurity Profiling: Regulatory scrutiny is high for the identification and control of process-related impurities and potential degradants. Suppliers must provide comprehensive impurity profiles and validated analytical methods for their materials. The acceptable limits for specific impurities are set by [Sponsor Company] in consultation with regulatory authorities.

What is the Geographic Concentration of Lazcluze Suppliers?

The geographic distribution of Lazcluze suppliers shows a concentration in regions with established pharmaceutical manufacturing infrastructure and expertise.

• Asia (Primarily India and China): These regions are dominant for the production of many chemical intermediates, including Chiral Building Block X and Core Ring Structure Y. Supplier 1 and Supplier 3 are based in these regions. Cost-effectiveness and large-scale manufacturing capabilities are key drivers for sourcing from these locations.

• Europe: European CDMOs, such as CDMO A, are significant players in API manufacturing, particularly for complex molecules requiring advanced synthesis and stringent quality control. Their regulatory compliance and established GMP infrastructure are highly valued.

• North America: While some intermediate suppliers may be located here, the primary API manufacturing, as indicated by CDMO B’s operations, is also represented in this region. This may be due to proximity to [Sponsor Company]'s R&D facilities or strategic decisions regarding supply chain resilience.

What are the Potential Risks and Mitigation Strategies for the Lazcluze Supply Chain?

Several risks are associated with the current Lazcluze supply chain, necessitating proactive mitigation strategies.

• Single Sourcing: Reliance on a single supplier for critical intermediates poses a significant risk of disruption due to manufacturing issues, geopolitical instability, or natural disasters.

  • Mitigation: Dual sourcing for Chiral Building Block X and Core Ring Structure Y is recommended. Engaging with qualified secondary suppliers for these intermediates should be a priority.

• Geopolitical Tensions: Concentration of suppliers in specific geopolitical regions can lead to supply chain vulnerabilities due to trade disputes, export restrictions, or regional conflicts.

  • Mitigation: Diversifying the geographic base of critical suppliers, including API and key intermediate manufacturers, across different continents is advisable.

• Intellectual Property (IP) Infringement: As process patents are filed and expire, there is a risk of IP disputes or the emergence of unauthorized generic manufacturers.

  • Mitigation: Continuous monitoring of patent landscapes and engagement with legal counsel to protect IP rights are essential.

• Capacity Constraints: As Lazcluze progresses through late-stage clinical trials and toward commercialization, the demand for API and intermediates will increase. Existing suppliers may face capacity limitations.

  • Mitigation: Early engagement with CDMOs to secure long-term manufacturing agreements and capacity reservations is crucial. Exploring partnerships with additional CDMOs for commercial supply should commence in Phase III trials.

Key Takeaways

The supply chain for Lazcluze API is characterized by a reliance on specialized CDMOs with advanced synthetic capabilities. Key intermediates originate from a geographically diverse but consolidated supplier base. Regulatory compliance, particularly GMP adherence and DMF filings, is paramount for all manufacturing partners. Risks include single sourcing and geopolitical vulnerabilities, necessitating proactive diversification and capacity planning.

Frequently Asked Questions

1. What is the primary therapeutic area for Lazcluze? Lazcluze is an investigational drug targeting [Disease Area].

2. Which regulatory bodies are most critical for Lazcluze API manufacturing approvals? The U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) are critical, along with other national regulatory authorities in target markets.

3. How is the chirality of Lazcluze API maintained during synthesis? Chirality is maintained through specialized processes such as enzymatic resolution or asymmetric synthesis, typically involving a key chiral building block.

4. What is the estimated timeline for Lazcluze API manufacturing to scale up for commercial supply? Scaling up for commercial supply typically begins during Phase III clinical trials, with full commercial manufacturing capacity established in anticipation of regulatory approval, often requiring 18-24 months lead time.

5. Are there any publicly disclosed timelines for Lazcluze’s potential market entry? No definitive market entry timelines are publicly disclosed at this stage of investigational drug development.

Citations

[1] [Placeholder for specific patent filing document reference, e.g., US Patent No. X,XXX,XXX, Inventor(s) A, B, C, Assignee: Sponsor Company, Date of Grant: YYYY-MM-DD] [2] [Placeholder for specific regulatory filing document reference, e.g., FDA Orange Book Entry, EMA Public Assessment Report] [3] [Placeholder for industry news or press release, e.g., CDMO B Announces Partnership with Sponsor Company, Date: YYYY-MM-DD, Source: [News Outlet]] [4] [Placeholder for technical publication or conference abstract, e.g., Poster Presentation at [Conference Name], Title: Novel Synthetic Route for Lazcluze Intermediate, Author(s): D, E, F] [5] [Placeholder for company website or investor relations report, e.g., CDMO A Capabilities Overview, Accessed: YYYY-MM-DD]